top of page

workshop: Global health drug development


The need for innovation in development of and access to healthcare products for global health applications has never been greater, while at the same time the issues facing the developers and manufacturers have never been more complicated.

Developing and distributing medicines and vaccines for a global market involves expanded challenges and issues for the parties involved.  Done well, these developments are smooth alliances between multi-functional organizations funded by both public and private organizations.  Optimally, the resulting products benefit not just traditional markets but also those in less developed countries and regions.  In order to achieve these goals, certain elements are essential:

  • Innovation

  • Development capabilities

  • Funding sources

  • Global clinical trials

  • The strategic and social use of intellectual property

  • Alliance capabilities

  • Distribution networks

Join the Global Health Innovation Alliance Accelerator and the Triangle Global Health Consortium on April 4th for a workshop exploring the concerns facing start up companies, spin-offs from universities, institutes, the US government and traditional pharmaceutical companies as they partner to develop and distribute new medicines and vaccines.


Attendees will gain practical skills and knowledge on a broad range of issues, including meeting requirements for partnering with the NIH, foundations, and clinical trial organizations; negotiating license agreements; and managing clinical trials in low and middle income countries.  Networking opportunities will be incorporated throughout the day.

Hosted by

Global Health Innovation Alliance Accelerator

Triangle Global Health Consortium


NC Biotech Center

15 TW Alexander Dr, Durham, NC 27703


Tuesday, April 4, 9:00am-4:00pm


Professionals - $65

Students - $40


8:30-9:00 AM


9:00-9:15 AM

Introductions and Welcome

Julie Barnes-Weise, Claire Neal

9:15-9:35 AM

Critical needs in global health development

Chris Woods

9:35-10:05 AM

Vaccine development challenges for emerging diseases

Kevin Gilligan

10:05-10:35 AM

The role of patents in building a building a global health product business

Arles Taylor

10:35-11:00 AM

The impact of the FDA on global health product development through incentives such as the Priority Review Voucher system

Jeffrey Moe

11:00-11:15 AM


11:15-11:45 AM

Life cycle management versus evergreening – how the rest of the world looks at the US and EU pharma market patents.  How will access be addressed?

Rosa Castro

11:45-12:15 PM

Building a sustainable global health business – non-profit or for profit

Rita Khanna

12:15-12:45 PM

Panel: Developing country markets - the economics of partnering a global health product

Rita Khanna and Vishy Pingali

12:45-1:30 PM

Lunch: Federal funding and global health, a look ahead

Greg McDonald

1:30-1:45 PM

Universities as alliance innovators

Mark Crowell

1:45-2:00 PM

The role of a university technology office in finding partners for global health technologies

Robin Rasor

2:00-2:15 PM

The GHIAA Tech Transfer Access to Medicines survey project

Robin Rasor and Kushal Kadakia

2:15-2:45 PM

Ownership of data in a global licensing and development agreement

Julie Watson

2:45-3:05 PM

Alliances for increasing access to medicines for outbreaks and less developed countries

Julie Barnes-Weise

3:05-3:20 PM


3:20-3:40 PM

Bringing global technologies home – licensing with an international institute

Kevin Boggs

3:40-4:10 PM

Panel: Global health licensing

Julie Barnes-Weise, Kevin Boggs, Mark Crowell, Julie Watson

4:10-4:30 PM

Q&A and conclusions



bottom of page